article thumbnail

Polypharmacy is a Health Killer: Personalized Medication Management is the Answer

MedCity News

We cannot change the fact that some patients must take multiple drugs, but we can certainly change how we manage it with careful coordination and communication among healthcare providers, and personalized medicine practices such as pharmacogenomics.

article thumbnail

How Counterfeit Medicines Challenge Pharma Sales in Malaysia

Contrarian Sales Techniques

Counterfeit medicines aren’t just a risk to patients’ health – they’re a blow to the industry’s reputation and our efforts to promote genuine, high-quality treatments. What Are Counterfeit Medicines? Counterfeit medicines are fake drugs that may contain incorrect ingredients, the wrong dose, or even harmful substances.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

In Europe, shortages of Novo Nordisk's Ozempic to persist into Q4: letter

Fierce Pharma

The company and the European Medicines Agency warned European healthcare providers to continue limiting new patient prescriptions until the shortages let up.

article thumbnail

Can Herbal Alternatives Ease the Economic Burden of Weight Loss Drugs?

MedCity News

For patients who may be unable to afford the high cost of GLP-1 obesity drugs or are worried about the side effects, it’s important for healthcare providers to offer education on herbal alternatives and consider these as part of the broader treatment conversation. appeared first on MedCity News.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine.

article thumbnail

US FDA approves Blueprint Medicines’ indolent systemic mastocytosis therapy

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has granted approval for Blueprint Medicines’ Ayvakit (avapritinib) as the first and only treatment for indolent systemic mastocytosis (ISM) in adult patients. The precision therapy has been designed for potently and selectively inhibiting KIT D816V, which is the main underlying driver of the disease.

article thumbnail

Pharma Research Trends: Leveraging Innovation for Smarter Marketing Strategies

Pharma Marketing Network

From AI-powered insights to the rise of precision medicine, new trends are reshaping the way we connect with patients and healthcare providers. Pharma research provides the data and insights needed to create targeted campaigns. Pharma research provides the data and insights needed to create targeted campaigns.